SOMA NEWS HIGHLIGHTS Media Articles Related to Soma (Carisoprodol)
Chromosomal Problems Affect Nearly All Human Embryos; Discovery May Explain Low Fertility Rates In Humans
Source: Fertility News From Medical News Today [2009.07.02]
For the first time, scientists have shown that chromosomal abnormalities are present in more than 90% of IVF embryos, even those produced by young, fertile couples.
Genetic And Chromosomal Abnormalities In Embryos Detected By New Test
Source: Clinical Trials / Drug Trials News From Medical News Today [2009.07.01]
One-step screening for both genetic and chromosomal abnormalities has come a stage closer as scientists announced that an embryo test they have been developing has successfully screened cells taken from spare embryos that were known to have cystic fibrosis.
$500,000 Gruber Genetics Prize Awarded To Cancer Geneticist Janet Davison Rowley
Source: Cancer / Oncology News From Medical News Today [2009.07.02]
Janet Davison Rowley, MD, a founder in the field of cancer cytogenetics and a renowned leader in molecular oncology, will receive the 2009 Genetics Prize of The Peter and Patricia Gruber Foundation. She is being honored with the prestigious international award for discoveries of recurrent chromosomal abnormalities in leukemias and lymphomas - discoveries that have revolutionized how cancer is understood and treated.
Evidence Challenges Effectiveness Of Embryo Screening For Older Women
Source: Fertility News From Medical News Today [2009.07.02]
There is growing evidence that a procedure for identifying chromosomal abnormalities in embryos prior to in vitro fertilization is ineffective at helping older women become pregnant, the Wall Street Journal reports. The procedure -- known as pre-implantation genetic screening, or PGS -- is performed in dozen of U.S.
Combating Blood Flukes By Using Gene Map
Source: Blood / Hematology News From Medical News Today [2009.06.30]
The first microsatellite-based genetic linkage map has been published for Schistosoma mansoni, a blood fluke that is known to infect over 90 million people in Africa, the Middle East and the New World. Researchers writing in BioMed Central's open access journal Genome Biology hope the map will stimulate research and open doors to new advances in combating this neglected human pathogen. S.
Published Studies Related to Soma (Carisoprodol)
Double-blind, placebo-controlled trial of carisoprodol 250-mg tablets in the treatment of acute lower-back spasm. [2008.02]
PURPOSE: The objective of this placebo-controlled trial was to determine the efficacy and safety of carisoprodol (Soma, MedPointe Pharmaceuticals, Somerset, NJ, USA), a centrally acting skeletal muscle relaxant used to treat acute, painful musculoskeletal conditions, at a dosage of 250 mg three times daily and at bedtime in patients with acute, painful muscle spasm of the lower back... CONCLUSIONS: In this study, patients with acute muscle spasm of the lower back had significantly greater and more rapid relief from starting backache, and had improved functional status, as measured by the RMDQ, during treatment with carisoprodol 250-mg tablets compared to placebo. Patients experienced clinical improvement with or without sedation.
Cognitive-behavioural therapy for patients with multiple somatoform symptoms--a randomised controlled trial in tertiary care. [2004.04]
OBJECTIVE: (a) To evaluate the effect of a cognitive-behavioural inpatient treatment and (b) to analyse the differential efficacy of an additional ("soma") group management training of somatisation... CONCLUSION: Considering the subjects' high initial impairment, the outcome results are encouraging. The specific effect on health care use highlights the socioeconomic relevance. Copyright 2004 Elsevier Inc.
Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. [2003.01.01]
CONCLUSION: Concomitant radiochemotherapy increased overall survival and locoregional control rates. The difference between the two treatment groups for Grade 3-4 complications was only significant for the teeth. The late toxicity assessment of a treatment may depend on the toxicity scale used. The LENT/SOMA scale seems to be the most accurate scale, but most of the score results were not concordant with those obtained with other scales. The results of this study confirm the necessity of using a common late toxicity scale in clinical trials.
Treatment with the specific estrogen receptor antagonist ICI 182,780 demasculinizes neuron soma size in the developing zebra finch brain. [2008.12.30]
In zebra finches, many features of the neural song system are more pronounced in males compared to females. The exact mechanism(s) responsible for these differences are unknown, but may involve steroid hormones.However, reported inconsistencies about sex differences in estrogen exposure and/or utilization exist, suggesting that complete sexual differentiation and development likely involve additional factors.
Somatostatin infusion increases intestinal ischemia and does not improve vasoconstrictor response to norepinephrine in ovine endotoxemia. [2008.11]
Hemodynamic support of patients with septic shock is often complicated by a tachyphylaxis against exogenous catecholamines...
Clinical Trials Related to Soma (Carisoprodol)
Prevention of Radiation Pneumonitis After Three-Dimensional Conformal Radiation Therapy (3D-CRT) in Patients With Non-Small-Cell Lung Cancer [Recruiting]
The purpose of this study is to evaluate the interest of breath holding for the prevention of
radiation pneumonitis following conformal radiation therapy.
Eligible patients will be randomly assigned in a 2-arm trial to free breathing or breath
holding during conformal radiation.
The primary objective of the study is to establish the efficacy of breath holding, compared
to free breathing, in the prevention of early pulmonary toxicity following conformal
radiation.
Several departments of radiotherapy, many pneumology units and two basic and applied research
laboratories take part in this multicentric study.
The number of patients required to demonstrate a reduction in radiation pneumonitis from 45 %
to 22. 5 %, assuming an alpha risk of 5% in a two-sided test and 95% power, is 240 (120 per
arm). With a planned accrual of 7 patients per month, it is estimated that the inclusion
period should be approximately 3 years.
Parotid-Sparing Intensity-Modulated Radiation Therapy Compared With Conventional Radiation Therapy in Treating Patients With Oropharyngeal or Hypopharyngeal Cancer Who Are at High Risk of Radiation-Induced Xerostomia [Active, not recruiting]
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells.
Intensity-modulated radiation therapy delivers thin beams of radiation of different strengths
directly to the tumor from many angles. This type of radiation therapy may reduce damage to
the parotid (salivary) glands, prevent xerostomia (dry mouth), and improve quality of life.
It is not yet known whether intensity-modulated radiation therapy is more effective than
conventional radiation therapy in preventing xerostomia and improving quality of life in
patients who have throat cancer.
PURPOSE: This randomized phase III trial is studying intensity-modulated radiation therapy to
see how well it works compared to conventional radiation therapy in treating patients with
oropharyngeal or hypopharyngeal cancer who are at risk of developing xerostomia caused by
radiation therapy.
Trial of Safety Nets In Hospitalized Patients [Completed]
This study compared standard hospital restraints to a newer safety net restraint system to
compare them for acceptability, tolerance, duration of restrain, length of stay in the
hospital, and satisfaction of MD, nurse, and relatives of patients.
A Pharmacogenetic Investigation of Antipsychotics in Schizophrenia and Schizophrenia-Like Psychoses [Recruiting]
An individual's genetic make-up is known to determine their response to antipsychotic
medication. Genetic markers that determine efficacy and side effects of medication may be
identified and used to predict treatment outcome.
The study is a naturalistic study of routinely prescribed antipsychotics using outcome
measures undertaken as part of the routine clinical care of the cohort. These clinical data
are linked with genetic information obtained from DNA and RNA from blood samples undertaken
as part of the study.
No alteration is made to the subjects treatment regime or medication.
The study is a two stage investigation:
- The first stage involves the collection of a databank of clinical information and blood
samples for DNA and RNA extraction from patients treated with antipsychotic medication.
- The second stage is a molecular genetic investigation of treatment-related genetic
factors that may contribute to response prediction and predisposition to side effects.
From these genetic studies pharmacogenetic prediction tests will be validated and/or
developed.
Study to Determine if Hyperbaric Oxygen Therapy is Helpful for Treating Radiation Tissue Injuries [Recruiting]
The principle objective of this research is to more precisely determine the degree of benefit
that hyperbaric oxygen therapy affords in the treatment of late radiation tissue injury.
The study has eight* components. Seven involve the evaluation of established radionecrosis
at varying anatomic sites (mandible, larynx, skin, bladder, rectum, colon, and gyn). The
eighth will investigate the potential of hyperbaric oxygen (HBO) therapy to prophylax against
late radiation tissue injury.
*(One of the arms, HORTIS IV - Proctitis has been closed to further patient recruitment. This
decision was based on an interim statistical analysis which generated sufficient evidence to
support closing down this arm of HORTIS.)
|
